Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results (Businesswire) - Aug 1, 2024 - "The Company anticipates Japanese regulatory authorities' approval of LUPKYNIS in the second half of this year, based on the JNDA that Otsuka filed in November 2023 for approval of LUPKYNIS to treat adults with LN. Upon approval, the Company expects to receive a milestone payment of $10 million with low double-digit royalties on net sales once launched....Achieved 22% growth in patients on LUPKYNIS therapy, with approximately 2,336 patients on therapy as of June 30, 2024, compared to 1,911 as of June 30, 2023....Additionally, the Company is moving forward with development of its pipeline asset AUR200...First patients are expected to enter the Phase 1 Single Ascending Dose (SAD) study of AUR200 in the third quarter of 2024. Data from the SAD study, including safety, tolerability, pharmacokinetics, and biomarkers, is anticipated in the first half of 2025."
Commercial • Japan approval • New P1 trial • P1 data • Immunology • Lupus Nephritis
|